Bio­gen scores a pri­or­i­ty re­view for its Alzheimer's drug ad­u­canum­ab, mov­ing one gi­ant leap for­ward in its con­tro­ver­sial quest

Bio­gen scored a big win at the FDA to­day as reg­u­la­tors ac­cept­ed their ap­pli­ca­tion for the con­tro­ver­sial Alzheimer’s drug ad­u­canum­ab and gave it a pri­or­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER